B. Riley Sees Multi-Billion Dollar Potential in Elicio’s mKRAS Vaccine B. Riley sees Elicio as a strong Buy; mKRAS cancer vaccine data in June could be a major stock catalyst. Credit: Elicio Therapeutics Subscribe now Already have an account? Sign in.
